Atossa Therapeutics (ATOS)

• Market cap: $25.3M
• 1 day: -1.93%
• 5 days: -3.05%
• 1 month: 5.83%
• 3 months: -48.89%
• 6 months: -35.86%
• Year to date: -73.15%
• 1 year: -77.24%
• 5 years: -94.95%
• 10 years: -99.62%
• Sector: Healthcare
• Industry: Biotechnology

About: Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.

Employees: 14